These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 16275831)
1. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W; Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831 [TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Pappert EJ; Germanson T; Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S; J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type B for cervical dystonia. Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248 [TBL] [Abstract][Full Text] [Related]
7. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type B for cervical dystonia. Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474 [TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Figgitt DP; Noble S Drugs; 2002; 62(4):705-22. PubMed ID: 11893235 [TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448 [TBL] [Abstract][Full Text] [Related]
14. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685 [TBL] [Abstract][Full Text] [Related]
15. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065 [TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Lew MF; Brashear A; Factor S Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982 [TBL] [Abstract][Full Text] [Related]
17. An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia. Chinnapongse R; Pappert EJ; Evatt M; Freeman A; Birmingham W Int J Neurosci; 2010 Nov; 120(11):703-10. PubMed ID: 20942584 [TBL] [Abstract][Full Text] [Related]
18. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. Samotus O; Lee J; Jog M J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988 [TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Lew MF; Adornato BT; Duane DD; Dykstra DD; Factor SA; Massey JM; Brin MF; Jankovic J; Rodnitzky RL; Singer C; Swenson MR; Tarsy D; Murray JJ; Koller M; Wallace JD Neurology; 1997 Sep; 49(3):701-7. PubMed ID: 9305326 [TBL] [Abstract][Full Text] [Related]